Clinical trials: Essential Hypertension.
Primary Hypertension
Effects of Telmisartan/Hydrochlorothiazide Treatment in Hypertensive Patients Under Real-life Setting
One of the most common adverse effects resulting from the therapy with thiazides, thiazide-like diuretics and loop diuretics is increased potassium secretion.
- Trial name
- POTASSIUM (NCT01392534)
- Testing
- Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103)
- Where
- Poland
- Volunteers
- 1,586 people
- Sponsor
- Bayer
Hypertension,Essential, Systolic Hypertension
Cardiac Neuromodulation Therapy (CNT) "Washout" Sub-Study
This washout protocol is structured as a sub-study for patients willing to participate after finishing the double blind randomised phase of the clinical trial, NCT02837445. Devices will be turned off for a week approximately.
- Trial name
- NCT05086523
- Testing
- Programmable Hypertension Control (BackBeat Moderato), Pacing (BackBeat Moderato)
- Where
- 6 sites in Czechia, Hungary and 1 more
- Volunteers
- 28 people
- Sponsor
- BackBeat Medical Inc
Essential Hypertension
Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian Patients With Essential Hypertension
The trial is designed to assess the safety and investigation of the efficacy of a single oral dose of bisoprolol (Nerkardou - Nerhadou) oral dissolvable film (ODF) 5 \& 10 mg, and patients' compliance in the treatment of…
- Trial name
- BETTER (NCT05880056)
- Testing
- Nerkardou (5 mg) & (10 mg)
- Where
- Egypt
- Volunteers
- 406 people
- Sponsor
- Genuine Research Center, Egypt
Essential Hypertension
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
A multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients with Essential Hypertension Inadequately Controlled with AGLS
- Trial name
- NCT05503953
- Testing
- AGSAVI, AGLS
- Where
- South Korea
- Volunteers
- 318 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Essential Hypertension
Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension
This study is an exploratory Phase 1 randomized, double-blind (Investigator and study subject and 2-D echo endpoint assessor), placebo-controlled single IV infusion dose escalation study that will enroll up to approximately 32…
- Trial name
- NCT01873885
- Testing
- Experimental: Single IV Infusion Vasomera (PB1046)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Essential Hypertension
Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension
This study was a non-interventional, secondary use of data, retrospective, cohort study, and the data to be extracted in this study was used as secondary use of collected patient information in the database (Japan Medical Data…
- Trial name
- NCT06604897
- Where
- United States
- Volunteers
- 1,405 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Observation of the Efficacy and Tolerance of Motens® (Lacidipine) in Patients With Essential Hypertension
Study of the efficacy and tolerance of Motens® (lacidipine) in patients with essential hypertension. To obtain information on the dosage used in practice and the tolerance at the start of treatment (12 weeks)
- Trial name
- NCT02235415
- Testing
- Motens® (lacidipine)
- Volunteers
- 24,526 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients
The purpose of this study is to evaluate of efficacy and safety of HCP1904-2 and RLD2001-2 alone in patients with essential hypertension inadequately controlled on RLD2001-2 monotherapy.
- Trial name
- NCT04830449
- Testing
- HCP1904-2, RLD2001-2
- Where
- South Korea
- Volunteers
- 122 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Essential Hypertension
Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects
The objective of this study is to determine the safety and tolerability and to determine the Pharmacokinetic and Pharmacodynamic (PK/PD) of ascending single oral dose of BR-A-657 in healthy male subjects.
- Trial name
- NCT01289886
- Testing
- BR-A-657
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
HYPERTENSION, HYPERCHOLESTEROLEMIA
A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia
This 10-12 week study will provide data on the safety and efficacy of using 320 valsartan and 80 mg simvastatin together compared to using either one alone in lowering blood pressure and LDL cholesterol.
- Trial name
- NCT00171093
- Testing
- valsartan + simvastatin
- Where
- United States
- Volunteers
- 369 people
- Sponsor
- Novartis
Hypertension
Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate Hypertension
This is an open-label, non-comparative, multi-centre clinical study to evaluate the Efficacy and safety of Metoprolol Succinate prolonged-release tablet (Betaloc Zok) in patients with mild to moderate essential hypertension.
- Trial name
- NCT00861016
- Testing
- metoprolol succinate prolonged-release tablet and felodipine
- Volunteers
- 310 people
- Sponsor
- AstraZeneca
Hypertension
Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension
The purpose of this study is to compare the antihypertensive effect of azilsartan medoxomil versus placebo in Korean adults with essential hypertension.
- Trial name
- NCT02203916
- Testing
- Azilsartan medoxomil
- Where
- 15 sites in South Korea
- Volunteers
- 328 people
- Sponsor
- Takeda
Essential Hypertension
A Bioequivalence Study of L04TD3 Compared to Administration of L04RD1 in Healthy Volunteers
This is a randomized, open, single-dose, crossover-design, phase 1, singlecenter study to evaluate bioequivalence after administration of L04RD1 or administration of L04TD3 in healthy volunteers.
- Trial name
- NCT05993806
- Testing
- L04RD1, L04TD3
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Celltrion
Hyperlipidemias, Hypertension
Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab
The purpose of this study is to evaluate the effectiveness of Olostar Tablet on blood pressure and lipid profiles, obtain safety-related information for subgroups that failed to participate in the clinical trials, and to evaluate…
- Trial name
- NCT05411887
- Testing
- Rosuvastatin, Olmesartan Medoxomil
- Where
- South Korea
- Volunteers
- 2,845 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Essential Hypertension, Dyslipidemia
A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia
The objective of this clinical study is to evaluate the efficacy and safety by comparing the fimasartan/atorvastatin treatment group to the fimasartan/placebo treatment group and the placebo/atorvastatin treatment group…
- Trial name
- FIESTA (NCT03338426)
- Testing
- Fimasartan 120mg, Atorvastatin 40mg
- Where
- South Korea
- Volunteers
- 133 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356)
This study has two parts. In the first part, the efficacy and safety MK-0954E (losartan potassium 50 mg [L50] (+) hydrochlorothiazide 12.5 mg [H12.5] (+) amlodipine besylate 5mg [A5]) will be evaluated and compared to the…
- Trial name
- NCT01299376
- Testing
- L50/H12.5/A5, L50/H12.5
- Volunteers
- 286 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension
Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension
This post-marketing surveillance study was designed to supplement under conditions of normal clinical practice the data on the safety, tolerability and efficacy of Micardis® collected during the clinical studies.
- Trial name
- NCT02176850
- Testing
- Micardis®
- Volunteers
- 19,870 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Bioimpedance Evaluation of Therapeutic Titration in Essential, Refractory Hypertension
To determine whether impedance cardiography (ICG) parameters can predict favorable or unfavorable blood pressure (BP) response and time to BP control prior to initiation or intensification of specific antihypertensive drug…
- Trial name
- BETTER-HTN (NCT00913094)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- CardioDynamics
Essential Hypertension With Stable Angina and Dyslipidemia
A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.
The purpose of this study is to evaluate the effects of oral azilsartan once daily for 32 weeks on coronary artery plaque in essential hypertensive patients with stable angina and dyslipidemia.
- Trial name
- ALIVE (NCT02400775)
- Testing
- Azilsartan
- Where
- Japan
- Sponsor
- Takeda
Hypertension
Efficacy and Safety of Moxonidine in Indian Patients
The purpose of this study is to demonstrate efficacy and safety of Moxonidine in Indian subjects.
- Trial name
- NCT00160277
- Testing
- Moxonidine
- Where
- 3 sites in India
- Volunteers
- 100 people
- Sponsor
- Solvay Pharmaceuticals